ISRCTN67723958已完成不适用
Rotterdam Aphasia Therapy Study - 2
Erasmus Medical Center (The Netherlands)0 个研究点目标入组 160 人开始时间: 2006年10月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aphasia due to stroke
- •2. Within three weeks post onset
- •3. Age 18 to 85 years
- •4. Language near native Dutch
- •5. Life expectancy more than six months
排除标准
- •1. Severe dysarthria
- •2. Premorbid dementia
- •3. Illiteracy
- •4. Severe developmental dyslexia
- •5. Severe visual perceptual disorders
- •6. Existing aphasia
- •7. Subarachnoidal haemorrhage
- •8. Recent psychiatric disorder
研究者
相似试验
进行中（未招募）
不适用
A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma - THYRRAD, CRAD001CNL08TPatients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus).EUCTR2009-016669-27-NLeiden University Medical Center
已完成
2 期
A phase II study to investigate the efficacy of RAD001 (Afinitor ®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinomathyroid cancerNL-OMON35047eids Universitair Medisch Centrum42
已完成
不适用
A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.unresectable colorectal cancerJPRN-UMIN000022535Gunma University45
进行中（未招募）
1 期
Essai thérapeutique de phase IIA évaluant l'efficacité du Bortezomib (velcade) chez les patients atteints de la maladie de Waldenstrom en phase avancée - WM2Maladie de Waldenstrom réfractaire ou en rechute après une ou deux lignes de traitement ayant comporté des alkylants et/ou des analogues de purine et/ou un anticorps monoclonal seul ou en association.MedDRA version: 8.1 Level: PT Classification code 10054695 Term: Macroglobulinémie de WaldenströmEUCTR2006-004218-42-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)34
进行中（未招募）
不适用
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI